Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s stock has been of interest for both individual investors and Wall Street analysts recently. Let’s look at the crowd and equity research sentiment so that we can get a solid idea as to where the shares might be headed. Should we buy, sell or hold?

Zacks collects broker services based on the information provided by 14 analysts. These services are then Zacks into their five-point ratings scale, allowing for easier interpretation for private investors. This differs from the Crowd Ratings scale, because Zacks numbers work in the opposite direction. Zacks says one is a “Strong Buy” and five is a Strong Sell. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s ABR (average broker rating) is 1.97.

Street analysts anticipate that the social media giant would post quarterly share earnings of $0.01. The actual earnings that the firm reported last quarter was $-0.09. Interested parties will be awaiting the moment when Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will reveal their actual results on 2017-01-25.

Now let’s look at the Closing Bell. Individual investors can rate a stock according a sliding scale where “one” is a Strong Sell and “five” is a Strong Buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s crowd consensus rating is 3.6. This rating is derived from the 15 ratings provided by individuals investors.

Brokerage Firm Analysts View

Private investors also pay attention to how Wall Street researchers react to stocks. Zacks Research, a well-respected research firm with over 30 years of experience, compiles all of this brokerage data and then produce rankings and predictive data. Wall Street sell-side analysts anticipated that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares will reach a high of $75-$139. The consensus target is at $105.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.